Could a cancer drug also fight wasting? tiny trial aims to find out
NCT ID NCT07146893
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tests whether selpercatinib, a drug already used for certain cancers, can help with cachexia (severe weight loss and appetite loss) in people with advanced lung, colon, or pancreatic cancer. Seven participants will take the drug twice daily for 12 weeks, with regular weight checks and questionnaires. The goal is to see if weight stabilizes or improves, and if the drug is practical to take.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Selpercatinib (RETEVMO), a drug taken orally twice daily
What this could lead to
If it works, this could point toward a treatment for cancer-related weight loss and poor appetite, improving quality of life.
What could go wrong
This is a very early, small feasibility study with only 7 participants. It may not show clear benefit, and side effects of selpercatinib are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
OU Health Stephenson Cancer Center
Oklahoma City, Oklahoma, 73117, United States
Contact Email: •••••@•••••
Contact